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In their current paper, Kourelis et al. profile the different
immune cells within the bone marrow (BM) of patients with
POEMS syndrome (polyneuropathy, organomegaly,
endocrinopathy, M-protein, skin changes) (Kourelis et al.,
2019). POEMS syndrome is a paraneoplastic entity, due to an
excessive inflammatory reaction that is related to a mono-
clonal plasma cell population (Keddie & Lunn, 2018). Eleva-
tions of pro-inflammatory cytokines, such as interleukin 1b,
interleukin 6, and tumour necrosis factor a, have all been
found, while elevated vascular endothelial growth factor levels
contribute by endothelial cell activation and increasing vascu-
lar permeability (Dispenzieri & Buadi, 2013). The malignant
component of this disorder is only small, while most of the
symptoms (polyneuropathy, skin changes and lymph node
disorders) are caused by the chronic inflammation.
Further deciphering this inflammatory reaction urged
Kourelis et al. to perform mass cytometry on BM samples
from patients with POEMS syndrome and compare these
profiles with patients with monoclonal gammopathy of unde-
termined significance (MGUS) because these patients also
present a monoclonal gammopathy, but without the systemic
complications seen in POEMS syndrome.
The authors introduced mass cytometry to profile the dif-
ferent immune cells. In the past, this profiling was com-
monly done by flow cytometry. Instead of fluorochrome-
labelled antibodies, mass cytometry uses heavy metal isotopes
to label antibodies, and the labelled cells are analysed by
high-throughput spectrometry (Galli et al., 2019). In this
way, mass cytometry or cytometry by time-of-flight (Cytof)
fuses the principles of mass spectrometry and flow cytome-
try. Up to 50 parameters can be studies per cell. Because
staining and acquisition is simultaneously realised, the risk of
technical sample variations between samples is reduced. This
makes Cytof suitable for automated analysis of large sample
groups, in which even rare immune subsets can be identified.
Cytof was previously used in other plasma cell disorders to
illustrate the immune modulatory action of daratumumab in
multiple myeloma (Adams et al., 2019), to profile immune
cell populations in myeloma and precursor cell entities at
diagnosis (Kourelis et al., 2019; Marsh-Wakefield et al., 2019;
Bailur et al., 2019) and in case of resistant disease to daratu-
mumab or immunomodulatory agents (Neri et al., 2018).
Although the number of patients that were included in
this study was low, the authors identified in their current
work different subsets within CD4 and CD8 cells. More
interestingly, increases in double-positive T cells and pro-
grammed cell death protein 1 (PD-1)-positive CD4 T cells
were seen in the BM of patients with POEMS (Kourelis
et al., 2019). The overexpression of PD-1 was not confirmed
by immunohistochemistry on BM sections.
The potential implication of the PD-1/programmed death
receptor-ligand 1 (PDL-1) axis in the pathophysiology
reminds us on the therapeutic efficacy of nivolumab in
Hodgkin lymphoma (Ansell et al., 2015). This lymphoma
entity is also characterised by sparse malignant cells (Hodg-
kin and Reed–Sternberg [HRS] cells) that constitute <5% of
the tumour bulk, but HRS cells grow and survive with the
help of interactions with and within a heterogeneous back-
ground of inflammatory cells. Different immune checkpoint
regulators are expressed by HRS cells, but PD-L1 is found to
be universally present on HRS cells due to a genetic amplifi-
cation at chromosome 9 (De Goycoechea et al., 2019). This
overexpression explains the therapeutic efficacy of immune
checkpoint inhibition in this malignancy.
The current work of Kourelis et al. illustrates well the
capacities of mass cytometry: it gives insights into the patho-
physiology of diseases and allows the discovery of novel tar-
gets or biomarkers. Profiling of immune subsets is currently
its main application, but the fast development of this tech-
nique will allow a broadening to other fields.
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